Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension
← catalyst calendarSponsored by CVRx, Inc. (industry) · CVRX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40actual
Sites
9
Countries
Canada, Germany, Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2011 | not stated | When the study began enrolling |
| Primary completion | May 2012 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2011-11-16 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- High Blood Pressure
Interventions
- Device: BAROSTIM NEO System — also filed as XR-1 System, Neo System
- Drug: Medical Management
Primary outcome
what the primary-completion date above is the date OFTo access long-term adverse events in participants implanted with the BAROSTIM NEO System.
measured For the duration of the study, up to 10 years.
Publications
- PMID 28065708 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CVRX's whole pipeline · Catalyst calendar · Every registered study · What changed